Gilead Sciences Inc. GILD, -0.18% said Monday it has reached a deal to acquire CymaBay Therapeutics Inc. CBAY, +2.92% for $32.50 per share in cash, a 27% premium to CymaBay's closing price Friday, for
Unlike many other market segments, biotech stocks stand out for their direct relevance. For example, investors who typically wager on aerospace and defense plays usually aren't fighter pilots.
Shares of Kyverna Therapeutics jumped 55.7% in their market debut on Thursday, giving the biopharmaceutical company that is backed by Gilead Sciences a market capitalization of $1.4 billion.

Why Gilead Sciences Stock Dropped Today

03:48pm, Wednesday, 07'th Feb 2024
Gilead delivered a mixed fourth quarter relative to expectations. The biopharma giant also issued underwhelming forward guidance.
Mastercard today announced that its Board of Directors has declared a quarterly cash dividend of 66 cents per share. The cash dividend will be paid on May 9, 2024 to holders of record of its Class A c
Gilead (GILD) posts mixed results for the fourth quarter. Sales beat estimates on the better-than-expected performance of Veklury due to higher hospitalizations at the end of 2023.
Brian Belski, chief investment strategist at BMO Capital Markets, joins 'Halftime Report' to break down his latest trades.
Gilead Sciences, Inc. (GILD) Q4 2023 Earnings Call Transcript
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estima
Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.
Gilead came up with a mixed fourth quarter late Tuesday as sales of its Covid treatment bolstered sales. GILD stock slipped in late trades.
Gilead Sciences on Tuesday said its fourth-quarter revenue dipped 4% on lower sales of HIV drugs and Veklury, an infused drug for hospitalized COVID-19 patients, while its adjusted profit rose 3% due
Investors of Lilly (LLY) are responding to the eye-opening efficacy of obesity drugs Mounjaro and Zepbound.
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.

3 Top Pharma Stocks to Buy Now: February 2024

05:00pm, Thursday, 01'st Feb 2024
Looking for pharma stocks to buy in February 2024? The pharmaceutical industry has always drawn a big crowd of investors.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE